Cingulate (NASDAQ: CING) grants 60,000 options tied to FDA approval milestone
Rhea-AI Filing Summary
Cingulate EVP and CFO Jennifer L. Callahan received two grants totaling 60,000 stock options on July 16, 2026, each with an exercise price of $4.4300 per share and expiring July 16, 2036.
For both grants, 25% vests on March 31, 2027, with the remainder vesting in substantially equal monthly installments over the following 36 months. For 19,800 options, vested options become exercisable only if the NDA for CTx-1301 is approved by the FDA during 2027; if that approval is not obtained in 2027, this grant, including any vested portion, terminates.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Callahan Jennifer L.
Role
EVP and CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to Buy) F1 | 40,200 | $0.00 | $0.00 |
| Grant/Award | Stock Option (right to Buy) F1, F2, F3 | 19,800 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to Buy) — 60,000 shares (Direct)
Footnotes (3)
- F1. The option vests as follows: 25% on March 31, 2027 and the remaining shares in substantially equal monthly installments over the 36-month period following the initial vesting date.
- F2. Vested option only becomes exercisable if the Issuer's NDA for CTx-1301 is approved by the FDA during 2027.
- F3. If the Issuer's NDA for CTx-1301 is not approved by the FDA during 2027, the option, including any vested portion, shall terminate.
Key Figures
Time-vested options granted: 40,200 options
Performance-contingent options granted: 19,800 options
Exercise price: $4.4300 per share
+3 more
6 metrics
Time-vested options granted
40,200 options
Stock options granted to EVP and CFO on 2026-07-16 with standard vesting
Performance-contingent options granted
19,800 options
Options granted on 2026-07-16, exercisable only if 2027 FDA NDA for CTx-1301 is approved
Exercise price
$4.4300 per share
Exercise price for both option grants reported on 2026-07-16
Option expiration date
July 16, 2036
Expiration date for both stock option grants
Initial vesting tranche
25% on March 31, 2027
Initial vesting date for both option grants
Remaining vesting period
36 months
Remaining shares vest in substantially equal monthly installments after March 31, 2027
Key Terms
Stock Option (right to Buy), NDA, CTx-1301, vests
4 terms
Stock Option (right to Buy) financial
"security title is reported as "Stock Option (right to Buy)""
NDA regulatory
"Vested option only becomes exercisable if the Issuer's <b>NDA</b> for CTx-1301 is approved"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
CTx-1301 medical
"If the Issuer's NDA for <b>CTx-1301</b> is not approved by the FDA during 2027"
vests financial
"The option <b>vests</b> as follows: 25% on March 31, 2027 and the remaining shares"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Cingulate (CING) report for Jennifer L. Callahan?
Cingulate reported that EVP and CFO Jennifer L. Callahan received two stock option grants on July 16, 2026, totaling 60,000 options. Both grants are exercisable at $4.4300 per share and expire on July 16, 2036, subject to detailed vesting and performance conditions.
How many stock options were granted to the Cingulate (CING) CFO and on what terms?
Jennifer L. Callahan was granted 40,200 and 19,800 stock options, each with an exercise price of $4.4300 per share and a July 16, 2036 expiration. Both follow a time-based vesting schedule starting March 31, 2027, with additional conditions on part of the award.
What is the vesting schedule for the new Cingulate (CING) stock options?
The options vest as follows: 25% of each grant vests on March 31, 2027, and the remaining shares vest in substantially equal monthly installments over the subsequent 36 months. This vesting structure applies to both the 40,200 and 19,800 option grants.
How is FDA approval of CTx-1301 linked to the Cingulate (CING) option grant?
For the 19,800-option grant, vested options become exercisable only if the issuer’s NDA for CTx-1301 is approved by the FDA during 2027. If that NDA is not approved in 2027, the entire grant, including any vested portion, terminates.
Are the Cingulate (CING) CFO’s new option grants immediately exercisable?
No, the options are not immediately exercisable. They first vest over time, with 25% vesting on March 31, 2027, and the remainder monthly over 36 months. In addition, 19,800 options require 2027 FDA approval of the CTx-1301 NDA before they can be exercised.